Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05340491 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Name: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial — clinical trial record (NCT05340491)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorSun Yat-sen University

Started2022-04-01

View on ClinicalTrials.gov ↗

Amendment history

2026-05-06

Study Status, Contacts/Locations v2

Primary completion date2024-12→2026-12

Completion date2027-12→2028-12

2022-08-30

Study Status v1

Start dateestimated 2022-04→confirmed 2022-04-01

2022-04-21

Original filing

Sun Yat-sen University

609 trials monitored

See 13 trials at risk

Head & Neck Cancer

2,051 trials monitored

See 116 trials at risk

This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

Trial Details

NCT Number	NCT05340491
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Carcinoma
Enrollment	212 participants
Start Date	2022-04-01
Primary Completion	2026-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-11